Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

"(1) Safety introduction phase (6 cases): 250mg, oral, QD,after one cycle of combined treatment, the occurrence of DLT was evaluated: 1) If ≤1person occurs, continue the dose expansion study at that dose level. 2)In the event of DLT\> 1, then the dose of surufatinib was adjusted to 200mg，oral，QD,until disease progression or intolerance of toxicity.~(2) Dose expansion phase (24 cases): RP2D, oral, QD,until disease progression or intolerance of toxicity."

1500mg, Q4W.iv.every 28 days; until disease progression or intolerance of toxicity.